Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Diflunisal. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACMSD | Q8TDX5 | 6/20 | 0.97 |
| ▸ | TTR | P02766 | 2/20 | 0.97 |
| ▸ | DHFR | P00374 | 2/20 | 0.97 |
| ▸ | CA1 | P00915 | 2/20 | 0.97 |
| ▸ | CA2 | P00918 | 2/20 | 0.97 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.97 |
| ▸ | MEN1 | O00255 | 1/20 | 0.97 |
| ▸ | USP2 | O75604 | 1/20 | 0.97 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.97 |
| ▸ | LMNA | P02545 | 1/20 | 0.97 |
| ▸ | ALB | P02768 | 1/20 | 0.97 |
| ▸ | HMGB1 | P09429 | 1/20 | 0.97 |
| ▸ | HPGD | P15428 | 1/20 | 0.97 |
| ▸ | CXCL12 | P48061 | 1/20 | 0.97 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.97 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.97 |
| ▸ | SLC22A6 | Q4U2R8 | 1/20 | 0.97 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.97 |
| ▸ | MCL1 | Q07820 | 7/20 | 0.51 |
| ▸ | HNF4A | P41235 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Diflunisal SCHEMBL4337 | 0.98 | ACMSD (1.00) | ACMSDTTRDHFRCA1CA2 | |
| Diflunisal SCHEMBL3848363 | 0.98 | ACMSD (1.00) | ACMSDTTRDHFRCA1CA2 | |
| Diflunisal SCHEMBL29367380 | 0.98 | ACMSD (1.00) | ACMSDTTRDHFRCA1CA2 | |
| Diflunisal SCHEMBL30509654 | 0.98 | ACMSD (1.00) | ACMSDTTRDHFRCA1CA2 | |
| Diflunisal SCHEMBL28916416 | 0.97 | ACMSD (0.97) | ACMSDTTRDHFRCA1CA2 | |
| Diflunisal SCHEMBL11425421 | 0.97 | ACMSD (0.97) | ACMSDTTRDHFRCA1CA2 | |
| Diflunisal SCHEMBL20876816 | 0.97 | ACMSD (0.97) | ACMSDTTRDHFRCA1CA2 | |
| Diflunisal SCHEMBL1869144 | 0.97 | ACMSD (0.97) | ACMSDTTRDHFRCA1CA2 | |
| Diflunisal SCHEMBL28350701 | 0.94 | ACMSD (0.91) | ACMSDTTRDHFRCA1CA2 | |
| Diflunisal SCHEMBL6690010 | 0.93 | ACMSD (0.89) | ACMSDTTRDHFRCA1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250099491-A1 | PREVENTION OR TREATMENT OF CARDIOVASCULAR DISEASES WITH HIGH PENETRATION PRODRUGS OF ASPIRIN AND OTHER NSAIDS | TECHFIELDS INC. (JP) | 2025-03-27 | — | — | US | disclosed |
| EP-4465993-A1 | PREVENTION OR TREATMENT OF CARDIOVASCULAR DISEASES WITH HIGH PENETRATION PRODRUGS OF ASPIRIN AND OTHER NSAIDS | TECHFIELDS INC. (US) | 2024-11-27 | — | — | EP | disclosed |
| WO-2023134732-A9 | PREVENTION OR TREATMENT OF CARDIOVASCULAR DISEASES WITH HIGH PENETRATION PRODRUGS OF ASPIRIN AND OTHER NSAIDS | TECHFIELDS PHARMA CO., LTD. (CN) | 2024-08-08 | — | — | WO | disclosed |
| WO-2023134732-A1 | PREVENTION OR TREATMENT OF CARDIOVASCULAR DISEASES WITH HIGH PENETRATION PRODRUGS OF ASPIRIN AND OTHER NSAIDS | TECHFIELDS PHARMA CO., LTD. (CN) | 2023-07-20 | — | — | WO | disclosed |
| CN-105744983-B | Device and method for sustained release of therapeutic agents of low water solubility in solubilizing agents | 纳米医学系统公司 | 2019-12-27 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250099491-A1 | PREVENTION OR TREATMENT OF CARDIOVASCULAR DISEASES WITH HIGH PENETRATION PRODRUGS OF ASPIRIN AND OTHER NSAIDS | PTGS1, PTGIS, PTGS2 | ACMSD 13/4885TTR 995/4885DHFR 1001/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.